Latest Mapatumumab Stories
NEW YORK, June 2, 2011 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development.
CALGARY, March 24 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S.
SEATTLE, Feb. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
CALGARY, Feb. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
ROCKVILLE, Md., Feb. 4, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor.
CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
WALTHAM, Mass., Jan.
An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial.
A clinical trial of a potential new targeted treatment drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality.
NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Pfizer Inc.